构建针对c-MET的对抗性双对应双链的aptamers
Xiangru Zhang1,2, Nan Zhang1,2, Haojun Sun1,3
1Beijing National Laboratory for Molecular Sciences, Key Laboratory of Analytical Chemistry for Living Biosystems, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China.
Angewandte Chemie (International ed. in English)
|January 28, 2026
概括
研究人员将惰性体转化为c-MET信号传递的强有力的激活剂. 这些新型双价双链体 (BVDSApts) 诱导目标二分化和下游效应,提供新的治疗潜力.
科学领域:
- 分子生物学分子生物学
- 生物化学 生物化学
- 药物发现 药物发现 药物发现
背景情况:
- 胺是具有高亲和度结合的寡核酸,但通常抑制功能.
- 激活的阿普坦是罕见的,限制了它们的治疗应用.
- c-MET信号在细胞过程中至关重要,但需要特定的激活.
研究的目的:
- 为了设计一个生物惰性的体体到一个具有激动性活动.
- 开发针对c-MET的新型双价双链亚体 (BVDSApts).
- 为了研究工程性阿普他默诱导的c-MET激活的功能后果.
主要方法:
- 一个已知的c-MET吸收酶 (HF3-58) 的理性分子工程.
- 设计和合成具有不同中心双重长度的双价双链体 (BVDSApts).
- 在细胞中评估c-MET结合,二元化,酸化和下游信号.
主要成果:
- 工程BVDSApts显示了增强的c-MET结合,与他们的单链对应物不同.
- 优化的BVDSApts (18-22bp双排) 强烈诱导c-MET二分化和酸化.
- 诱导信号显著增强细胞迁移和分散,模仿HGF效应.
结论:
- 通过理性设计和序列工程,生物惰性体可以被设计成功能性激动剂.
- BVDSApts代表了一种具有激活向分子的能力的新型受体类.
- 这些工程性体具有作为治疗剂和HGF替代物的前体的潜力.
相关概念视频
Fixing Double-strand Breaks
14.6K
The double-stranded structure of DNA has two major advantages. First, it serves as a safe repository of genetic information where one strand serves as the back-up in case the other strand is damaged. Second, the double-helical structure can be wrapped around proteins called histones to form nucleosomes, which can then be tightly wound to form chromosomes. This way, DNA chains up to 2 inches long can be contained within microscopic structures in a cell. A double-stranded break not only damages...
14.6K
Fixing Double-strand Breaks
4.4K
4.4K
Lagging Strand Synthesis
61.3K
During replication, the complementary strands in double-stranded DNA are synthesized at different rates. Replication first begins on the leading strand. Replication starts later, occurs more slowly, and proceeds discontinuously on the lagging strand.
There are several major differences between synthesis of the leading strand and synthesis of the lagging strand. 1) Leading strand synthesis happens in the direction of replication fork opening, whereas lagging strand synthesis happens in the...
There are several major differences between synthesis of the leading strand and synthesis of the lagging strand. 1) Leading strand synthesis happens in the direction of replication fork opening, whereas lagging strand synthesis happens in the...
61.3K
Lagging Strand Synthesis
16.6K
16.6K
Adrenergic Agonists: Therapeutic Uses
1.9K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.9K
Glucagon-like Receptor Agonists
902
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
902


